Showing 41 - 49 of 49
Innovation policy can be a crucial component of governments' responses to crises. Because speed is a paramount objective, crisis innovation may also require different policy tools than innovation policy in non-crisis times, raising distinct questions and tradeoffs. In this paper, we survey the...
Persistent link: https://www.econbiz.de/10012585399
We examine the distribution of Federal support for chemistry Research and Development (R&D) performed at U.S. universities from 1990-2009. Federal R&D funding is an essential source of funds for investigator-driven research at the nation's universities. Previous studies have documented that...
Persistent link: https://www.econbiz.de/10012455127
Persistent link: https://www.econbiz.de/10013167232
Persistent link: https://www.econbiz.de/10013167234
The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated their widespread introduction, saving millions of...
Persistent link: https://www.econbiz.de/10013435127
We derive the optimal funding mechanism to incentivize development and production of vaccines against diseases with epidemic potential. In the model, suppliers' costs are private information and investments are noncontractible, precluding cost-reimbursement contracts, requiring fixed-price...
Persistent link: https://www.econbiz.de/10013462668
Persistent link: https://www.econbiz.de/10013361344
Concern exists that public funding of science is increasingly risk averse. Funders have addressed this concern by soliciting the submission of high-risk research to either regular or specially designed programs. Little evidence, however, has been gathered to examine the extent to which such...
Persistent link: https://www.econbiz.de/10013361975
Persistent link: https://www.econbiz.de/10011449660